1,170 reports of this reaction
5.1% of all GANCICLOVIR reports
#3 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #3 most commonly reported adverse reaction for GANCICLOVIR, manufactured by Bausch & Lomb Incorporated. There are 1,170 FDA adverse event reports linking GANCICLOVIR to CYTOMEGALOVIRUS INFECTION. This represents approximately 5.1% of all 22,779 adverse event reports for this drug.
Patients taking GANCICLOVIR who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is moderately reported among GANCICLOVIR users, representing a notable but not dominant share of adverse events.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for GANCICLOVIR:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 1,170 FDA reports for GANCICLOVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 5.1% of all adverse event reports for GANCICLOVIR, making it one of the most commonly reported side effect.
If you experience cytomegalovirus infection while taking GANCICLOVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.